Otsuka Pharmaceutical Co. Ltd.'s four-year effort to gain US approval for tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD) may be coming to fruition, with the company announcing Nov. 11 further top-line data from the Phase III REPRISE study. Other data from the study were released by the company six months ago.
The US FDA rejected an NDA for the new indication for tolvaptan back in 2013, citing the need for additional...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)